Activaero inhales €10.7m in series A
This article was originally published in Clinica
Executive Summary
Activaero, a German specialist in inhaled drug delivery technologies, has raised €10.7m ($15.8m) in its first round of venture financing. The series A round was led by BioMedPartners, and included VI Partners, Abalis Finance and Vesalius Biocapital I SICAR. The funds will go towards new product development and commercialisation. Gemünden-based Activaero's products – it currently has two on the market, the Akita and the Watchhaler – incorporate its controlled breathing technology that allows for more precise and patient-tailored delivery of inhaled therapeutics.